What’s ‘meaningful’ pharma innovation? House subcommittee talks incentives Leave a comment
A $50 million venture fund dedicated to blood-related fields and cell therapies emerged Thursday after spending about a year building out its initial investments in a handful of startups, including a Jennifer Doudna spinout working on new cancer and autoimmune therapeutics.
The 60-year-old New York Blood Center, a nonprofit that delivers blood products, transfusion medicine services and blood research across 17 states, has created the NYBC Ventures fund to back startups working on benign hematology, infectious diseases, cell therapies, devices, transfusion medicine and other areas.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 168,200+ biopharma pros reading Endpoints daily — and it’s free.
